We value your privacy

We use necessary cookies to make this site work, and Google Analytics to measure visits (it sets cookies and is not affected by the choices below). With your consent, we also use our own analytics cookies to understand how the site is used and improve it. Privacy policy

XOOBAY 数贝环球
金盒集团
金盒集团

金盒集团

Premier Elite

5
Products
0
Followers
2013
Established

Yisheng Biopharma completed its merger with a SPAC in five and a half months, and was officially listed on the NASDAQ stock exchange in the United States recently

Yisheng Biopharma completed its merger with a SPAC in five and a half months, and was officially listed on the NASDAQ stock exchange in the United States recently

The controlling company of YS Biopharma Co., Ltd. from Beijing, (hereinafter referred to as "YS Biopharma"), successfully completed a reverse merger with SPAC (Special Purpose Acquisition Company)Summit Healthcare Acquisition Corp. (SMIH), and was officially listed on the NASDAQ on March 17, with the stock code "YS".

YS Biopharma, as an international biopharmaceutical company, is committed to the discovery, development, production and commercialization of a new generation of vaccines and therapeutic biological agents, with a focus on infectious diseases and cancer.

The company's management team has extensive expertise and a global vision in the vaccine and pharmaceutical industry.

The company has developed the independently developed PIKA® immunomodulatory technology platform and a series of preventive and therapeutic biological agents targeting rabies, hepatitis B, influenza, coronavirus and cancer.

The company has wholly-owned R&D centers in Beijing, China, Singapore, and Maryland, USA, and a large-scale GMP vaccine production base in Shenyang, China.

YS Biopharma previously submitted a prospectus to the Hong Kong Stock Exchange on March 8, 2021, intending to be listed on the Hong Kong Main Board, with Morgan Stanley and Haitong International acting as joint sponsors at that time.

As of the close of trading on March 17,YS Biopharma (YS) closed at $10.14 per share, a sharp drop of 22%.

9e38c7ad189ef92976c31b33b11f341c_wNab4AZkBb88wAAAABJRU5ErkJggg==.png

At the end of September 2022, "YS Biopharma" announced that it had reached a merger agreement with SPAC "Summit Healthcare Acquisition" with a valuation of $849 million.

On March 1, 2023, SPAC held an extraordinary general meeting to consider and vote on the merger. YS Biopharma's revenue for the fiscal year ending March 2022 was RMB 502 million, with a net loss of RMB 100 million.

On March 14, 2023, SPAC: Summit Healthcare Acquisition disclosed documents showing that shareholders had approved the merger plan with Beijing YS Biopharma.

On March 17, Beijing Yisheng Biopharma will officially list on the NASDAQ under the stock ticker: YS.

Originally published on 金盒企业管理集团